FDA Accepts Roche’s sBLA for Gazyva®/Gazyvaro® (Obinutuzumab) as a Treatment for Lupus Nephritis

Roche announced  that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for...

March 06, 2025 | Thursday | News
Roche Reports Positive Phase III OUtMATCH Data, Strengthening Xolair® for Food Allergies

Roche announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored phase III OUtMATCH study, which provide fur...

March 06, 2025 | Thursday | News
Celon Pharma Announces Positive Phase 2 Results for CPL’36 in Treating Levodopa-Induced Dyskinesia in Parkinson's Disease

Celon Pharma S.A.  announces robust and positive Phase 2 clinical trial results for its PDE10A inhibitor (CPL’36), a novel, oral, once-daily med...

March 05, 2025 | Wednesday | News
GHIT Fund Marks Milestone with First Administration of Arpraziquantel to Preschool Children in Uganda

The Global Health Innovative Technology (GHIT) Fund is announcing a significant milestone: the first administration of arpraziquantel to preschool-aged chi...

March 05, 2025 | Wednesday | News
FibroBiologics Files Patent for Innovative Approach to Enhance Mitochondrial Performance Using Fibroblasts

FibroBiologics, Inc. a clinical-stage biotechnology company with over 160 issued and pending patents focused on the development of therapeutics and potenti...

March 05, 2025 | Wednesday | News
Myosin Therapeutics Secures Funding to Advance MT-125 for Glioblastoma, MT-110 for Addiction

 Myosin Therapeutics, Inc., a biotechnology company developing novel therapies for cancer and neurological disorders, has closed its second seed fundi...

March 04, 2025 | Tuesday | News
CStone Begins Phase I Trial of CS2009 Trispecific Antibody for Solid Tumors

CStone Pharmaceuticals, an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, announced that&nbs...

March 04, 2025 | Tuesday | News
Avecho Biotechnology Partners with Sandoz for Exclusive Australian Rights to CBD Insomnia Capsule

Avecho Biotechnology Limited  announced it has signed an exclusive ten-year development and licensing agreement with Sandoz Group AG ("Sandoz") for th...

March 04, 2025 | Tuesday | News
Celldex Reports Positive Phase 2 Results for Barzolvolimab in Chronic Urticaria

Celldex Therapeutics, Inc. announced  positive data on measurements of disease control and quality of life from the Company’s Phase 2 barzolvoli...

March 03, 2025 | Monday | News
Jasper Therapeutics Presents Promising Updated Data on Briquilimab for Mast Cell-Driven Diseases at AAAAI 2025

Jasper Therapeutics, Inc. (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit ...

March 03, 2025 | Monday | News
GSK Announces Positive Phase III Results for Depemokimab in Treating Chronic Rhinosinusitis with Nasal Polyps

GSK plc announced full results from the positive ANCHOR-1 and ANCHOR-2 phase III clinical trials assessing the efficacy and safety of depemokimab versus pl...

March 03, 2025 | Monday | News
Amgen and AstraZeneca's TEZSPIRE® Demonstrates Significant Efficacy in Phase 3 WAYPOINT Trial for Chronic Rhinosinusitis with Nasal Polyps

Amgen and AstraZeneca announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE® (tezepelumab-ekko) signi...

March 03, 2025 | Monday | News
Roche Group Unveils Promising Results from NIH-Sponsored OUtMATCH Study, Highlighting Xolair® as a Leading Treatment for Food Allergies

Roche Group announced new positive data from Stage 2 and Stage 3 of the National Institutes of Health (NIH)-sponsored Phase III OUtMATCH study, which provi...

March 03, 2025 | Monday | News
CARsgen Therapeutics Initiates First Patient Dosing of KJ-C2219 in Systemic Lupus Erythematosus Trial

CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors,...

February 28, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close